Skip to main content
Fig. 1 | Journal of Hematology & Oncology

Fig. 1

From: Elraglusib (9-ING-41), a selective small-molecule inhibitor of glycogen synthase kinase-3 beta, reduces expression of immune checkpoint molecules PD-1, TIGIT and LAG-3 and enhances CD8+ T cell cytolytic killing of melanoma cells

Fig. 1

Clinical response to elraglusib monotherapy in a patient with refractory melanoma. 54-year-old male with BRAFV600E refractory melanoma and multiple sites of disease, including multiple brain lesions and progressing on anti PD-1 plus BRAF/MEK inhibitor combination. After 4-week washout brain lesions progression evident on MRI. The patient was treated with single-agent elraglusib at 5 mg/kg and within 6 weeks most sites of disease had resolved by PET, as well as significant CNS tumour shrinkage. Post-12 weeks of therapy, there was complete resolution of lesions by PET and only cystic lesions noted on brain MRI. The patient continues in CR for over 36 months

Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us